ANIP Earnings Prediction
The chart below shows how ANIP performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ANIP sees a -1.09% change in stock price 10 days leading up to the earnings, and a +1.09% change 10 days following the report. On the earnings day itself, the stock moves by +1.43%. This data can give you a slight idea of what to expect for the next quarter's release.
ANIP Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
148.33M
12.52%
7.46%
Gross Margin
46.86%
-9.85%
-1.47%
Operating Margin
-13.28%
-213.70%
-432.00%
Net Margin
-16.29%
-316.05%
881.33%
EPS
-1.27
-382.22%
807.14%
No Data Available
ANIP Earnings Analysis
ANI Pharmaceuticals, Inc. Corporation (ANIP.O) Earnings Conference Call
Positive
Revenue Increase Driven by Demand: Total revenues of $148.3 million, an increase of 13% over the third quarter of 2023, driven by accelerating demand for Cortrophin Gel and continued strong growth for generics.
Cortrophin Gel Revenue Surge: Cortrophin Gel generated $52.6 million in revenues during the quarter, up 77% over the third quarter of 2023, reflecting increased volume on a record number of new patient starts.
EBITDA Performance Analysis: Adjusted non-GAAP EBITDA was $35.1 million, compared to $36.5 million in the prior year period, demonstrating strong operational performance despite slight fluctuations.
Acquisition Impact on EBITDA: The acquisition of Alimera closed on September 16, enhancing the Rare Disease business and expected to create substantial shareholder value driving $35 million to $38 million in adjusted non-GAAP EBITDA in 2025.
Strong Liquidity Position: The company ended the quarter with $145 million in unrestricted cash and has $641.3 million in principal value of outstanding debt, indicating strong liquidity and financial stability.
Negative
Established Brands Revenue Decline: The company reported a decrease in revenues from established brands, totaling $91.9 million, which represents a decline of 10% compared to the prior year period.
Operating Expenses Increase: Adjusted non-GAAP operating expenses increased by 23% to $45 million in the third quarter of 2024 due to increased employment-related costs.
Generics Segment Revenue Growth: The net revenues for the generics segment were $78.2 million, reflecting an increase of only 11% over the prior year period, indicating slower growth than expected.
EBITDA Decline Analysis: The company experienced a decrease in adjusted non-GAAP EBITDA from $36.5 million in the prior year period to $35.1 million in the third quarter, highlighting a decline in profitability.
Acquisition Impact on Financials: The acquisition of Alimera closed on September 16, which may have impacted the financial results for the quarter, reflecting only two weeks of revenue and expense activity.
ANIP FAQs
How does ANIP typically perform around its earnings report dates?
Is ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ANIP Earning Call Sentiment
ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ANIP.O
-1.54%Positive
The earnings call reveals mixed signals: strong revenue growth and positive market expansion for Cortrophin Gel, but a decrease in gross margin and high debt levels. The Q&A highlights optimism in generics and ophthalmology, but vague responses on payer landscape raise concerns. No shareholder return plan was mentioned. Given the market cap of $1.32 billion, these mixed factors suggest a neutral stock price movement, with potential for slight volatility due to the company's small-cap status.